Baseline characteristics of the study population
| Short-acting | Long-acting | Placebo | p-value | |
| Patients n | 41 | 46 | 41 | |
| Age yrs | 34.8±10.6 | 33.7±11.5 | 35.8 ± 12.3 | 0.687 |
| Sex F/M | 17/24 | 23/23 | 20/21 | 0.697 |
| PC20 mg·mL−1# | 1.03 0.60–1.78 | 0.89 0.54–1.47 | 1.00 0.64–1.58 | 0.911 |
| FEV1 ml | 3362±719 | 3195±611 | 3056±787 | 0.150 |
| FFV1 % pred | 88±13 | 86±14 | 83±17 | 0.315 |
| Patients on inhaled steroids before | 44 | 54 | 56 | 0.486 |
| the start of the trial % | ||||
| Perception indices | ||||
| Slope>Borg/% reduction in FEV1 | 0.12±0.06 | 0.11±0.08 | 0.11±0.06 | 0.834 |
| PS20>Borg at 20% reduction in | 4.4±2.9 | 3.6±1.8 | 4.2±2.0 | 0.222 |
| FEV1 |
Data are presented as mean±sd unless otherwise stated. FEV1: forced expiratory volume in 1 second
PC20: provocative concentration causing a 20% fall in FEV1
PS20: absolute perceptual magnitude
F: female
M: male
#: geometric mean (95% confidence interval)